Carman Alenson - Mar 31, 2023 Form 4 Insider Report for Prime Medicine, Inc. (PRME)

Role
Interim Chief Financial Officer and Chief Accounting Officer
Signature
/s/ Gabriela Morales-Rivera, attorney-in-fact
Stock symbol
PRME
Transactions as of
Mar 31, 2023
Transactions value $
$0
Form type
4
Date filed
4/4/2023, 08:22 PM
Previous filing
Oct 19, 2022
Next filing
Apr 20, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PRME Stock Option (right to buy) Award $0 +90.5K $0.00 90.5K Mar 31, 2023 Common Stock 90.5K $12.30 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/48th of the shares underlying this option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of March 31, 2023, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

Interim Chief Financial Officer and Chief Accounting Officer